{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:18:45Z","timestamp":1768274325799,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":1954,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1038\/ki.2010.191","type":"journal-article","created":{"date-parts":[[2010,7,30]],"date-time":"2010-07-30T08:10:05Z","timestamp":1280477405000},"page":"S33-S36","source":"Crossref","is-referenced-by-count":20,"special_numbering":"S117","title":["Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study"],"prefix":"10.1016","volume":"78","author":[{"given":"Neal","family":"Mittman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brinda","family":"Desiraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin B.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morrell M.","family":"Avram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2010.191_bb0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/MAJ.0b013e31803bb129","article-title":"Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease","volume":"333","author":"Khan","year":"2007","journal-title":"Am J Med Sci"},{"key":"10.1038\/ki.2010.191_bb0015","first-page":"S41","article-title":"The parathyroid-calcitriol axis in health and chronic renal failure","volume":"29","author":"Slatopolsky","year":"1986","journal-title":"Kidney Int"},{"issue":"Suppl 95","key":"10.1038\/ki.2010.191_bb0020","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1523-1755.2005.09500.x","article-title":"Consequences and management of hyperphosphatemia in patients with renal insufficiency","volume":"67","author":"Friedman","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.191_bb0025","first-page":"185","article-title":"Secondary hyperparathyroidism in chronic kidney disease: clinical consequences and challenges","volume":"31","author":"Michael","year":"2004","journal-title":"Nephrol Nurs J"},{"key":"10.1038\/ki.2010.191_bb0030","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.191_bb0035","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000073945","article-title":"Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product","volume":"23","author":"Moe","year":"2003","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2010.191_bb0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.mam.2008.04.001","article-title":"Vitamin D analogs: therapeutic applications and mechanisms for selectivity","volume":"29","author":"Brown","year":"2008","journal-title":"Mol Aspects Med"},{"key":"10.1038\/ki.2010.191_bb0045","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.semnephrol.2004.06.013","article-title":"Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism","volume":"24","author":"Martin","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1038\/ki.2010.191_bb0050","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00467-004-1788-2","article-title":"Are new vitamin D analogues in renal bone disease superior to calcitriol?","volume":"20","author":"Salusky","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"10.1038\/ki.2010.191_bb0055","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1517\/14656566.7.5.617","article-title":"Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease","volume":"7","author":"Cheng","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1038\/ki.2010.191_bb0060","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0149-2918(00)88299-5","article-title":"Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis","volume":"21","author":"Goldenberg","year":"1999","journal-title":"Clin Ther"},{"key":"10.1038\/ki.2010.191_bb0065","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1517\/14656566.9.6.947","article-title":"Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism","volume":"9","author":"Cozzolino","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1038\/ki.2010.191_bb0070","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1053\/ajkd.1998.v32.pm9808142","article-title":"Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats","volume":"32","author":"Slatopolsky","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.191_bb0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000046993","article-title":"Vitamin D analogs for the treatment of secondary hyperparathyroidism","volume":"20","author":"Slatopolsky","year":"2002","journal-title":"Blood Purif"},{"key":"10.1038\/ki.2010.191_bb0080","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1038\/sj.ki.5001981","article-title":"Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: a single center crossover study","volume":"70","author":"Mittman","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.191_bb0085","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.191_bb0090","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","article-title":"Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings","volume":"19","author":"Dobrez","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 5","key":"10.1038\/ki.2010.191_bb0095","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","article-title":"Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism","volume":"38","author":"Llach","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.191_bb0100","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1007\/s00467-006-0204-5","article-title":"Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients","volume":"21","author":"Seeherunvong","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"10.1038\/ki.2010.191_bb0105","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol","volume":"38","author":"Sprague","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.191_bb0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CNP65335","article-title":"Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients","volume":"65","author":"Joist","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2010.191_bb0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000109398","article-title":"Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis","volume":"28","author":"Ross","year":"2008","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2010.191_bb0120","first-page":"59","article-title":"Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients","volume":"22","author":"Capuano","year":"2009","journal-title":"J Nephrol"},{"key":"10.1038\/ki.2010.191_bb0125","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2215\/CJN.01760408","article-title":"Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients","volume":"3","author":"Shinaberger","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.191_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.0894-0959.2004.17308.x","article-title":"The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease","volume":"17","author":"Goodman","year":"2004","journal-title":"Semin Dial"},{"key":"10.1038\/ki.2010.191_bb0135","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium X phosphorus product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 6","key":"10.1038\/ki.2010.191_bb0140","first-page":"S77","article-title":"Electron beam tomography to image cardiovascular calcifications in hemodialysis patients","volume":"15","author":"Raggi","year":"2002","journal-title":"J Nephrol"},{"key":"10.1038\/ki.2010.191_bb0145","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJM197805042981805","article-title":"Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia","volume":"298","author":"Avram","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.191_bb0150","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/BF03345264","article-title":"Derangement of glucose metabolism in hyperparathyroidism","volume":"26","author":"Procopio","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"10.1038\/ki.2010.191_bb0155","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1081\/JDI-48229","article-title":"Parathyroid hormone levels, calcium-channel blockers, and the dyslipidemia of nondiabetic hemodialysis patients","volume":"27","author":"Zanos","year":"2005","journal-title":"Ren Fail"},{"key":"10.1038\/ki.2010.191_bb0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/ndt\/10.supp3.13","article-title":"Renal osteodystrophy: pathogenesis and management","volume":"3","author":"Gonzalez","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2010.191_bb0165","first-page":"S39","article-title":"Role of parathyroid hormone in uremic toxicity","volume":"8","author":"Massry","year":"1978","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.191_bb0170","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3349\/ymj.1996.37.5.350","article-title":"Studies on bone markers and bone mineral density in patients with chronic renal failure","volume":"37","author":"Ha","year":"1996","journal-title":"Yonsei Med J"},{"key":"10.1038\/ki.2010.191_bb0175","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/ki.2008.248","article-title":"High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death","volume":"74","author":"Blayney","year":"2008","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815544669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815544669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T04:21:12Z","timestamp":1544329272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815544669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":34,"alternative-id":["S0085253815544669"],"URL":"https:\/\/doi.org\/10.1038\/ki.2010.191","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}